Abstract
The compound 1-(2,6-dichlorophenyl)indolin-2-one (1), planned as a pro-drug of diclofenac (2), was easily synthesized in 94% yield by an intramolecular reaction in the presence of coupling agent (i.e., EDC). Compound 1 showed anti-inflammatory and analgesic activity without gastro-ulcerogenic effects. The chemical and enzymatic hydrolysis profile of the lactam derivative 1 does not indicate conversion to diclofenac (2). This compound is a new non-ulcerogenic prototype for treatment of chronic inflammatory diseases.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / adverse effects*
-
Anti-Inflammatory Agents / chemical synthesis*
-
Anti-Inflammatory Agents / chemistry
-
Anti-Inflammatory Agents / pharmacology
-
Carrageenan
-
Celecoxib
-
Diclofenac / adverse effects
-
Diclofenac / chemistry
-
Diclofenac / pharmacology
-
Drug Design*
-
Hydrolysis / drug effects
-
Indoles / chemical synthesis*
-
Indoles / chemistry
-
Indoles / pharmacology*
-
Lactams / blood
-
Lactams / chemistry
-
Male
-
Models, Molecular
-
Pyrazoles / adverse effects
-
Pyrazoles / pharmacology
-
Rats
-
Rats, Wistar
-
Stomach Ulcer / chemically induced*
-
Sulfonamides / adverse effects
-
Sulfonamides / pharmacology
Substances
-
Anti-Inflammatory Agents
-
Indoles
-
Lactams
-
Pyrazoles
-
Sulfonamides
-
Diclofenac
-
Carrageenan
-
Celecoxib